BREAKING NEWS! Artemisia Annua: German Researchers Confirm That Extracts Of The Plant Artemisia Annua Are Active Against SARS-CoV-2 Coronavirus
: German biotech researchers and chemists from the Max Planck Institute of Colloids and Interfaces (Potsdam, Germany) in close collaboration with virologists from Freie Universität Berlin have shown in laboratory studies that aqueous and ethanolic extracts of specially bred sweet wormwood plants (A. annua) are active against the SARS-CoV-2 coronavirus that has caused the COVID-19 pandemic. https://www.fu-berlin.de/presse/informationen/fup/2020/fup_20_107-beifuss-corona/index.html
It is the phytochemical extract called artemisinin from the Artemisia Annua plant that is the main active ingredient with efficacy against the SARS-CoV-2 coronavirus.
Detailed human clinical trials to test the efficacy of both teas and coffee containing A. annuas well as the anti-malaria drug artesunate are about to begin at the University of Kentucky's academic medical center.
For thousands of years, herbal folk medicines in Asia, Africa, and South America have been used to treat infectious diseases. Extracts of A. annua plants have been successfully employed to treat febrile diseases including malaria.
The phytochemical artemisinin is extracted from this plant and is the basis for the WHO-recommended anti-malaria combination therapies used in millions of adults and children each year with few, if any, side effects.
The usage of Artemisia Annua teas as malaria treatment is promoted as a natural combination therapy against infections, although the WHO strongly discourages their use amid concerns about the development of malaria drug resistance.
The German researchers set out to determine whether A. annua extracts ie pure artemisinin and related derivatives, and mixtures thereof may be active against the COVID-19 virus. These drugs would be attractive candidates for repurposing considering they have excellent safety profiles and are ready availability, rapidly scalable, and are relatively inexpensive.
Prof Dr Peter H. Seeberger who initiated and oversaw the study together with Dr Kerry Gilmore told Thailand Medical News, "Having worked with compounds derived from A. annua plants, I was familiar with the interesting activities of the plants against many different diseases, including a range of viruses. Therefore, we felt that exploring the activity of this plant against COVID-19 was worth the undertaking."
The A. annua leaves from a cultivated seed line grown by ArtemiLife Inc. in Kentucky, U.S., when extracted with absolute ethanol or distilled water, provided the best antiviral activity. The addition of either ethanolic or aqueous A. annua extracts prior to virus addition resulted in significantly reduced plaque formation. The ethanolic extract of both A. annua and coffee was found to be most active.
However, artemisinin alone does not present much antiviral activity.
Dr Klaus Osterrieder, Professor of virology at Freie Universität Berlin who conducted all activity assays said, "I was surprised to find that A. annua extracts worked significantly better than pure artemisinin derivatives and that the addition of coffee further enhanced the activity.”
Inorder to test the activity of A. annua extracts in the COVID-19, human clinical trials with teas and coffees containing A. annua leaves provided by ArtemmiLife Inc. are about to begin at the University of Kentucky's academic medical center.
Also, artesunate, an artemisinin derivative used to treat malaria will be used in a Phase 1/2 clinical trial as well.
Dr Jill Kolesar PharmD, co-leader of the Drug Development Program at Markey Cancer Center and professor in the University of Kentucky College of Pharmacy said, "The University of Kentucky and UK Markey Cancer Center are delighted to continue our collaboration with ArtemiLife to study this Kentucky-grown A. annua as a potential treatment for patients with COVID infections."
The research paper: Gilmore et al. Artemisia annua Plant Extracts are Active Against SARS-CoV-2 In Vitro, (2020) has been submitted for publication.
October 5th: UPDATE
: The research apper has finally been publsihed on a preprint server and is pending peer review for publication into a medical journal: https://www.biorxiv.org/content/10.1101/2020.10.05.326637v1
Read Also: https://www.thailandmedical.news/news/must-read-covid-19-treatment-calls-for-research-into-sod-3,-artemisia-annua-and-ashwagandha-as-possible-adjuvant-drugs-for-covid-19
For more about Artemisia Annua
and COVID-19, keep on logging to Thailand Medical News.
HELP! Please help support this website by kindly making a donation to sustain this website and also all in all our initiatives to propel further research: https://www.thailandmedical.news/p/sponsorship